EUVIMEDEUVIMED entdecken
Vergleichsstudie

Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score‐Matched Cohort

Jacob Schmidt iD, Bernhard Ralla, Andreas Maxeiner, Jorien Krediet, Holger Beutel, Ayoub Hidayat Allah, Nella Gagel, Henning Plage, Maha Ullmann, Robert Peters, Frank Friedersdorff, Martin Kanne

The Prostate · 2025-10 · 85 (14) · 1299-1306

DOI: 10.1002/pros.70016 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 16.07.2025. Verfasst von Jacob Schmidt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berli…. Hauptthemen laut MEDLINE: Lasers, Solid-State, Prostatic Hyperplasia, Prostatectomy, Minimally Invasive Surgical Procedures. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Holmium laser enucleation of the prostate (HoLEP) is a well‐established, size‐independent surgical treatment offering favorable perioperative outcomes. Recently, minimal invasive laser enucleation of the prostate (MiLEP) has been introduced as a miniaturized approach utilizing a 22 Fr endoscope. However, comparative perioperative data on MiLEP versus HoLEP remain scarce. Materials and Methods A retrospective propensity‐matched (PSM) cohort analysis was conducted, comparing the perioperative outcomes of the first 100 MiLEPs performed at our center versus standard HoLEP. After the PSM of 2187 patients, data from 200 patients (HoLEP: n = 100, MiLEP: n = 100) treated at a high‐volume laser center were analyzed. Key parameters included operative time, enucleated tissue volume, complication rates, and catheterization duration. Statistical significance was set at p < 0.05.

Results

Demographic characteristics, overall operative (36 vs. 35 min, p = 0.87), and enucleation times (22 vs. 23 min, p = 0.68) were comparable between MiLEP and HoLEP. However, MiLEP showed significantly shorter median morcellation times (5 vs. 3 min, p = 0.03), while coagulation time was longer (6 vs. 5 min, p = 0.02). Overall, complication rates were similar between both groups (15% vs. 16%, p = 0.85), with similar Clavien–Dindo distributions (Grade II: 13% vs. 11%; Grade IIIb: 2% in both groups). Recatheterization (8% vs. 4%, p = 0.23), macrohematuria requiring prolonged catheterization (1% vs. 5%, p = 0.1), and postoperative fever (4% vs. 5%, p = 0.73) showed no significant differences and were size‐independent across prostates < 30, 30–59, and > 60 mL.

Conclusion

Implementation of MiLEP is safe and feasible in a center with HoLEP experience, demonstrating comparable perioperative outcomes. The miniaturized approach maintains surgical efficiency across different prostate sizes while reducing instrument size. Further studies are necessary to evaluate long‐term functional outcomes and confirm the potential benefits of MiLEP regarding urethral trauma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lasers, Solid-StateProstatic HyperplasiaProstatectomyMinimally Invasive Surgical ProceduresLaser TherapyProstateHumansMaleRetrospective StudiesPropensity ScoreAgedMiddle AgedTreatment OutcomeOperative TimeCohort StudiesPostoperative Complications

Stichwörter der Autor:innen

complicationsholmiumlaser therapyminimal invasive laser enucleation of the prostateperioperative carepropensity score matchingprostateprostatic hyperplasia

Autor:innen und Institutionen

  • Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berlin, Germany.
  • Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany.

ORCID-Profile: Jacob Schmidt

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Schmidt, J., Ralla, B., Maxeiner, A., Krediet, J., Beutel, H., Allah, A. H., Gagel, N., Plage, H., Ullmann, M., Peters, R., Friedersdorff, F., & Kanne, M. (2025). Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score‐Matched Cohort. The Prostate, 85(14), 1299-1306. https://doi.org/10.1002/pros.70016

Vancouver

Schmidt J, Ralla B, Maxeiner A, Krediet J, Beutel H, Allah AH, et al. Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score‐Matched Cohort. The Prostate. 2025;85(14):1299-1306. doi:10.1002/pros.70016

BibTeX
@article{Schmidt2025,
  author = {Schmidt, Jacob and Ralla, Bernhard and Maxeiner, Andreas and Krediet, Jorien and Beutel, Holger and Allah, Ayoub Hidayat and Gagel, Nella and Plage, Henning and Ullmann, Maha and Peters, Robert and Friedersdorff, Frank and Kanne, Martin},
  title = {Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score‐Matched Cohort},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {14},
  pages = {1299--1306},
  doi = {10.1002/pros.70016}
}
Kostenlos starten →